Literature DB >> 8128980

Case report: silent thyroiditis developed during alpha-interferon therapy.

K Kamikubo1, R Takami, T Suwa, Y Kawase, J Shiroko, M Kametani, N Tokimitsu, S Sakata.   

Abstract

Alpha-interferon (IFN-alpha) was used for the treatment of chronic active hepatitis C in a 30-year-old woman who was euthyroid but had low titers of antithyroid antibodies before treatment. Two months after the initiation of IFN-alpha therapy she became thyrotoxic. She had nontender diffuse goiter. A laboratory examination revealed elevated levels of serum free thyroid hormones and a suppressed concentration of serum thyrotropin. Titers of antimicrosomal antibodies increased. The anti-thyrotropin receptor antibody was negative. A 99mTcO- scintigram of the thyroid showed reduced uptake. During the IFN therapy free thyroid-hormone levels started to decline. The IFN-alpha therapy was completed 1 month after the onset of thyrotoxicosis. Two months after the completion of the therapy the patient became euthyroid and 99mTcO- uptake was normalized. It is likely that preexisting chronic thyroiditis was exacerbated to cause silent thyroiditis during IFN-alpha therapy. None of the other 11 patients with chronic hepatitis C who had had no anti-thyroid antibodies and were treated with IFN-alpha showed anti-thyroid antibodies and thyroid dysfunction after the therapy. It is advisable to assess anti-thyroid antibodies and thyroid function in patients who are going to receive IFN-alpha treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8128980     DOI: 10.1097/00000441-199309000-00009

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  3 in total

1.  De Quervain's Thyroiditis Associated with Interferon-alpha-2b Therapy for Non-Hodgkin's Lymphoma.

Authors:  A Fortis; C Christopoulos; E Chrysadakou; E Anevlavis
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

2.  Subacute thyroiditis during interferon-alpha therapy for chronic hepatitis C.

Authors:  P Falaschi; A Martocchia; R D'Urso; A Proietti
Journal:  J Endocrinol Invest       Date:  1997-01       Impact factor: 4.256

Review 3.  Clinical use of sensitive assays for thyroid-stimulating hormone.

Authors:  P A Masters; R J Simons
Journal:  J Gen Intern Med       Date:  1996-02       Impact factor: 5.128

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.